Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 12/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007992 | 0.88 | MC4R (0.39) | MC4RPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4006509 | 0.87 | MC4R (0.38) | MC4RPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4146475 | 0.76 | MC4R (0.48) | MC4RKCNH2 | |
| SCHEMBL4304841 | 0.75 | KCNH2 (0.53) | MC4RLMNAKCNH2 | |
| SCHEMBL4823163 | 0.74 | KDM4E (0.40) | MC4RPTGDR2MEN1KMT2AALDH1A1 | |
| SCHEMBL4363678 | 0.72 | KDM4E (0.40) | MC4RPTGDR2MEN1KMT2AALDH1A1 | |
| Formic Acid SCHEMBL4821760 | 0.71 | MC4R (0.41) | MC4RMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4369399 | 0.71 | MC4R (0.43) | MC4RMEN1KMT2AKCNH2 | |
| SCHEMBL4006716 | 0.71 | KCNH2 (0.51) | MC4RLMNAKCNH2 | |
| SCHEMBL4363739 | 0.71 | MC4R (0.65) | MC4RKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| WO-2009080351-A1 | COMPOUNDS WITH ANTI-EMETIC EFFECT | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-1644337-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Gene Logic, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| EP-1363890-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002062766-A2 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | WO | disclosed |